Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab + Chemotherapy as Neoadjuvant/Conversion Therapy in HER2+ Gastric/GEJ Adenocarcinoma
NCT07685704Phase 2Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of zanidatamab in gastric cancer (GC), gastroesophageal junction adenocarcinoma. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
zanidatamab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07685704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07685704.